Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Cost Reimbursement
Drugs
Locations
Clinical Specialty
221-240 of 991 trials

Hematologic Malignancies: MK-1026 Treatment Study

We are evaluating a new treatment for patients with blood cancers to see if it is safe and effective in reducing symptoms. This study focuses on various types of hematologic malignancies, including CLL and MCL.

Blood CancerEfficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHematologyOncology

Cancer Treatment: Imipramine for Fascin1 Overexpression

We are studying whether Imipramine can change tumor characteristics in patients with cancer that over-express a protein called Fascin1. This research may help us understand its effects on tumor behavior and markers.

Colon and Rectal Cancer3-6 monthsEfficacy phase (II)Standard MedicinesCost ReimbursementGastroenterologyOncology

Triple-Negative Breast Cancer: MK-2870 with Pembrolizumab

We are studying a new treatment combining MK-2870 and pembrolizumab for people with triple-negative breast cancer who had surgery but did not respond completely. The trial aims to see if this combination works better than standard treatment options.

Triple Negative Breast Cancer>2 yearsConfirmation phase (III)11-15 visitsNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Advanced Breast Cancer: Capivasertib with CDK4/6 Inhibitors

We are studying a new treatment combining capivasertib with CDK4/6 inhibitors and fulvestrant for patients with advanced hormone receptor-positive, HER2-negative breast cancer. The goal is to see if this combination improves treatment outcomes compared to standard therapies.

Hormone Receptor-Positive and HER2-Negative Breast Cancer3-6 monthsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncology

Long-Term Study of Delandistrogene Moxeparvovec (SRP-9001)

We are assessing the long-term safety and effectiveness of delandistrogene moxeparvovec in individuals who previously participated in a clinical study. This research aims to understand how the treatment continues to affect participants over time.

Duchenne Muscular Dystrophy>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementNeurologyOrthopedics and Traumatology

Advanced Solid Tumors: Amivantamab Treatment Study

We are studying a new treatment called amivantamab for patients with advanced or metastatic solid tumors, including those with EGFR-mutated lung cancer. The goal is to see how well it works when combined with other therapies.

Non-small Cell Lung CancerEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Advanced Non-Squamous NSCLC: Dato-DXd with Rilvegostomig

We are studying if a new treatment combination is safe and effective compared to pembrolizumab for patients with advanced non-squamous lung cancer. This trial is for those with high PD-L1 levels and no specific genetic changes.

Non-Small Cell Lung CancerConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Colorectal Cancer: ABBV-400 Treatment Study

We are studying a new drug, ABBV-400, combined with standard treatments for adults with advanced colorectal cancer. The goal is to assess its safety and effectiveness in patients who have already been treated.

Metastatic Colorectal CancerEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Uveitis Treatment: Adalimumab vs. Mycophenolate Mofetil

We are studying whether adalimumab can improve outcomes for people with steroid-dependent non-infectious uveitis compared to the standard treatment. This trial will help us understand the effectiveness and safety of both medications.

Uveitis>2 yearsConfirmation phase (III)Monitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementOphthalmologyRheumatology

Childhood Onset Nephrotic Syndrome: Obinutuzumab vs. MMF

We are studying whether obinutuzumab is more effective and safer than MMF for children with childhood onset idiopathic nephrotic syndrome. We will also look at how these treatments affect fatigue and quality of life.

Childhood Idiopathic Nephrotic Syndrome1-2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementInternal MedicineNephrology

Spinal Muscular Atrophy: Risdiplam for Children

We are studying the effectiveness and safety of risdiplam in children with spinal muscular atrophy who have not improved after gene therapy. This research aims to see if risdiplam can help these patients regain function.

Spinal Muscular Atrophy (SMA)>2 yearsMonitoring phase (IV)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementNeurologyPediatrics

Non-Small Cell Lung Cancer: Fianlimab and Cemiplimab with Chemotherapy

We are studying if adding Fianlimab to Cemiplimab and chemotherapy is safer and more effective for adults with early-stage non-small cell lung cancer that can be surgically removed. This trial will help us understand the best treatment options for these patients.

Resectable Non-small Cell Lung Cancer>2 yearsEfficacy phase (II)16-20 visitsStandard MedicinesCost ReimbursementPartially RemoteOncology

Atopic Dermatitis: PF-07275315 and PF-07264660

We are investigating two new treatments for adults with moderate to severe atopic dermatitis. The study aims to see if they are more effective than a placebo in reducing eczema symptoms.

Atopic Dermatitis1-2 yearsEfficacy phase (II)6-10 visitsCost ReimbursementPartially RemoteAllergologyDermatology

Blood Pressure Response: Multi-Omics Study

We are exploring how specific biomarkers can predict the effectiveness of blood pressure medications for individuals. This study aims to improve treatment personalization and understand potential side effects.

Essential Hypertension3-6 monthsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementCardiologyInternal Medicine

Autism Spectrum Disorder: Sensorimotor Therapy and Oxytocin

We are exploring whether a new therapy combined with a single dose of oxytocin can improve social connections in children with autism. The goal is to see if this approach enhances their interactions with others.

Autism Spectrum Disorder>2 yearsConfirmation phase (III)≤5 visitsStandard MedicinesCost ReimbursementPsychiatry

Treatment-Resistant Depression: COMP360 Study

We are studying whether two doses of COMP360 can improve symptoms in adults with treatment-resistant depression. This trial includes psychological support to enhance treatment effects.

Major Depressive DisorderTreatment-Resistant Depression6-12 monthsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemotePsychiatry

Coronary Disease: Tirzepatide Study

We are exploring whether tirzepatide can improve heart health by changing plaque composition and blood flow in people with obesity and coronary artery disease. This study compares tirzepatide to a placebo to assess its effects.

Overweight and Obesity1-2 yearsConfirmation phase (III)Monitoring phase (IV)6-10 visitsStandard MedicinesCost ReimbursementPartially RemoteCardiologyEndocrinology

Diffuse Large B-Cell Lymphoma: Epcoritamab with R-CHOP

We are studying whether adding Epcoritamab to standard R-CHOP treatment helps people with newly diagnosed Diffuse Large B-Cell Lymphoma live longer without disease progression. This trial compares the new combination to R-CHOP alone.

Diffuse Large B-Cell Lymphoma1-2 yearsConfirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

JAK1 Inhibitor for Large Inflammatory Liver Adenomas

We are studying whether the oral medication baricitinib can help reduce the size of large inflammatory liver adenomas in patients. This trial also looks at the safety and effectiveness of this treatment compared to standard care.

Hepatocellular Adenoma>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementGastroenterologyHepatology

Advanced Melanoma: IMC-F106C Plus Nivolumab

We are studying a new treatment combination for people with previously untreated advanced melanoma. The goal is to see if it helps patients live longer and have better outcomes compared to standard treatment.

Advanced Melanoma1-2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteDermatologyOncology